iMD Companies and Its Subsidiary, Riize Health, Announce New Verticals With White Label and Licensing
05 déc. 2024 08h30 HE
|
iMD Companies, Inc.
RANCHO CORDOVA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- IMD Companies, Inc. (OTC:ICBU) and its subsidiary, Riize LLC (Riize Health), is pleased to announce the launch of our white label and...
Licensing International Honors Joseph Kaminkow, Maca Rotter, and Stu Seltzer at 2024 Hall of Fame Event
04 déc. 2024 17h11 HE
|
Licensing International Foundation
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Licensing International, the leading trade association for the $356-billion global brand licensing industry, and the Licensing International Foundation,...
Theratechnologies annonce la conclusion d’un contrat de licence exclusive avec Ionis visant la commercialisation de l’olezarsen et du donidalorsen au Canada
04 déc. 2024 07h30 HE
|
Theratechnologies
L’ajout de médicaments expérimentaux ciblant l’ARN renforce le portefeuille fondamental de Theratechnologies dans le domaine du VIH Des demandes visant ces médicaments devraient être soumises à...
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
04 déc. 2024 07h30 HE
|
Theratechnologies
Addition of investigational RNA-targeted medicines build upon Theratechnologies’ foundational HIV portfolio Submissions to Health Canada planned for 2025 MONTREAL, Dec. 04, 2024 (GLOBE NEWSWIRE)...
The Smurf Experience - A 13,000-Square-Foot Family Attraction - Sets its U.S. Debut for Early 2025
20 nov. 2024 11h00 HE
|
SBX Group
Media kit link to high-res logos and images of the exhibition MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Following a record of success in Europe, The Smurf Experience will make its U.S. debut in...
Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
15 nov. 2024 04h30 HE
|
Numab Therapeutics AG; Kaken Pharmaceutical Co., Ltd.
Numab to receive R&D funding for the preclinical development of ND081 Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global...
Adeia Announces Third Quarter 2024 Financial Results
07 nov. 2024 16h12 HE
|
Adeia Inc.
Signed 7 deals across multiple verticals in the third quarterBoard increased share repurchase authorization up to $200 millionFiled patent infringement litigation against DisneySigned a new...
Playboy Enters Long-Term License Agreement for Condoms
16 juil. 2024 08h00 HE
|
PLBY Group, Inc.
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- PLBY Group, Inc. (NASDAQ: PLBY) (“PLBY Group” or the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most...
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.
25 juin 2024 08h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, June 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has entered into a worldwide license agreement with...
Technip Energies et Mitsubishi annoncent la signature d'un accord de licence pour la technologie d'alcool 'OXO M-Process'
10 juin 2024 12h05 HE
|
TECHNIP ENERGIES
Technip Energies (PARIS :TE) et Mitsubishi Chemical Corporation, filiale du groupe Mitsubishi Chemical, ont annoncé l'obtention d'une licence pour une technologie améliorée d'alcool OXO, appelée 'OXO...